A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol.

Trial Profile

A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2012

At a glance

  • Drugs AZD 9668; Budesonide/formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2011 Results published in Respiratory Medicine.
    • 26 Aug 2010 Actual end date added to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 26 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top